Investors seeking stability in their investments should consider Alcon, according to JPMorgan. The bank recently upgraded the eye care company’s stock from neutral to overweight. Additionally, JPMorgan raised its price target for Alcon to $89.30 per share from $79.80. This projection suggests a potential 11% increase from the previous day’s closing price of $80.24. Alcon’s positive outlook follows its impressive second-quarter results and increased full-year earnings guidance. Despite the stock’s modest response to these developments, analyst David Adlington believes that the company has various growth opportunities, particularly in its implantable segment and higher equipment volume. Adlington states, “The positive earnings’ momentum looks set to continue.” In 2023, Alcon’s stock has already surged by over 17%.